We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer
BMC Cancervolume 18, Article number: 53 (2018)
Moesin is a member of the ERM (ezrin, radixin and moesin) proteins that participate in cell migration and tumor invasion through transductional signals sent to actin filaments by glycoproteins, such as podoplanin.
This study aimed to evaluate the participation of moesin and podoplanin in the invasive tumor front of oral squamous cell carcinomas, and their influence on patients’ prognosis. Podoplanin and moesin immunoexpressions were evaluated by a semi-quantitative score method, based on the capture of 10 microscopic fields, at 400X magnification, in the invasive tumor front of oral squamous cell carcinomas. The association of moesin and podoplanin expression with clinicopathological variables was analyzed by the chi-square, or Fisher’s exact test. The 5 and 10 years survival rates were calculated by the Kaplan-Meier method and the survival curves were compared by using the log-rank test.
The immunohistochemical expression of moesin in the invasive front of oral squamous cell carcinomas was predominantly strong, homogenously distributed on the membrane and in the cytoplasm of tumor cells. The expression of moesin was not associated with clinical, demographic and microscopic features of the patients. Otherwise, podoplanin expression by malignant epithelial cells was predominantly strong and significantly associated with radiotherapy (p = 0.004), muscular invasion (p = 0.006) and lymph node involvement (p = 0.013). Strong moesin expression was considered an unfavorable prognostic factor for patients with oral squamous cell carcinomas, clinical stage II and III (p = 0.024).
These results suggested that strong moesin expression by malignant cells may help to determine patients with oral squamous cell carcinoma and poor prognosis.
Moesin is a member of the ERM (ezrin, radixin and moesin) family of proteins that plays a role in cellular morphology, cell adhesion, controlling adherent junctions and cell motility, the key events of the carcinogenesis processes [1,2,3]. Specifically, the metastatic process involves moesin and other ERM proteins, leading to changes in cell morphology, cell to cell adhesion and in actin filament reorganization .
Recently, the overexpression of moesin in tumors has been correlated with metastasis and poor prognosis for the patient [5,6,7,8], including those with oral squamous cell carcinomas [9, 10]. Moesin probably participates in necessary conformational changes for an appropriate cell configuration, flexible enough to allow extravasation . These processes occur through the phosphorylation of the C-terminal domain of moesin, which binds to actin filaments . In the other domain, N-terminal, transmembrane molecules, such as podoplanin, are able to activate it, consequently inducing Rho phosphorylation. These downstream signals result in loss of adhesion, motility and higher rates of cell proliferation .
Podoplanin is a transmembrane glycoprotein and its overexpression has been associated with enhanced cancer cell motility, tumor invasion and poor patient prognosis in head and neck tumors [14,15,16,17,18,19,20,21]. The role of podoplanin in the tumor invasion process was first hypothesized by Martin-Villar et al. (2005), who reported the activation of ERM proteins by podoplanin through Rho-A phosphorylation. This connection is responsible for the maintanance of the ERM proteins in an open and active state conformation, strengthening the anchorage of podoplanin to cytoskeleton filaments.
To gain further understanding of the participation of moesin in tumor invasion process and its association with podoplanin in this pathway, for the first time, we analyzed the immunohistochemical association of moesin and podoplanin in oral squamous cell carcinomas with clinicopathological features and patients’ prognosis.
This study was based on the analysis of eighty-four surgical specimens of patients who underwent surgical treatment for primary oral squamous cell carcinoma (OSCC) at the Head and Neck Surgery and Otorhinolaryngology Department of the A.C. Camargo Cancer Hospital, São Paulo, Brazil, from 1963 to 2012. Tumors were selected according to the following inclusion criteria: (1) oral squamous cell carcinoma located in the tongue, floor of the mouth, inferior gingiva and retromolar area, confirmed by biopsy; (2) patients not submitted to other previous treatment; (3) complete clinical data and follow up; (4) tumor tissue available for microscopic analysis. Clinical data were obtained from the medical records of the A.C. Camargo Cancer Hospital and included age, ethnic group, gender, tobacco and alcohol consumption, TNM stage (UICC: union for international cancer control, 2004), treatment (surgery, post-operative adjuvant radiotherapy), localization of the tumor and clinical follow-up (local recurrence, regional recurrence and death). Histopathological analysis included the following variables: vascular embolization, perineural infiltration, muscular infiltration, bone infiltration and lymph node involvement (pN+). Additionally, the histopathological grade of malignancy of oral squamous cell carcinomas was determined in hematoxylin & eosin stained sections .
Podoplanin and moesin immunoexpression in oral squamous cell carcinomas
The immunohistochemistry technique followed the protocol of the Department of Pathology of the A.C. Camargo Cancer Hospital used previously by Faustino et al. (2008). The tumors sections were incubated with following primary monoclonal anti-podoplanin antibody: D2-40 clone, Dako North America Inc., M3619, Glostrup, Denmark, dilution 1:200 and with anti-moesin antibody 38/87 clone, Neomarkers, USA, dilution 1:400. Palatine tonsil was used as positive control for anti-podoplanin antibody and placenta for anti-moesin antibody. The lymphatic vessels were used as internal control.
Approximately, 10 microscopic fields of each tumor specimen were captured with a digital camera (AxiocamMRc, Zeiss) attached to a microscope (Axioskop 2 Plus, Zeiss), at 400X magnification to evaluate the immunoexpression of podoplanin and moesin. Images of each tumor field were sequentially captured in the invasive tumor front and recorded in a computer program system (Axiovision 4.9, Zeiss, Jena, Germany).
Two experienced pathologists evaluated podoplanin and moesin expressions by malignant cells, based on a semi-quantitative score system, previously established by Faustino et al. (2008). The final score was determined by the sum of the immunostaining intensity and the percentage of positive immunostaining cells. Subsequently, the oral squamous cell carcinomas were classified into 3 groups: 0 = absent immunostaining; 1 = weak immunostaining; 2 = strong immunostaining .
The statistical analyses were performed using SPSS Statistical software version 21.0 (SPSS Inc., Chicago, IL, USA). The association of podoplanin and moesin immunoexpression by neoplastic cells with the clincopathological variables was verified by the Chi-square (x2), or Fischer’s exact tests. For these analyses, the absent and weak immunoexpressions were grouped together, obtaining a final group of absent/weak tumor immunoexpression and strong tumor immunoexpression. The overall survival probability in 5 and 10 years was estimated using the Kaplan-Meier method, and survival curves were compared by log-rank test. The follow-up period considered for overall survival consisted of the time between the date of surgery and death or the date of the last information about the patient. Cox regression analysis of the survival data was performed to test any statistical significance of regression coefficients. For all statistical analyses applied, p values of less than 0.05 were considered statistically significant.
For the present study, the sample consisted of 84 patients with oral squamous cell carcinomas, predominantly male (85.7%), white (95.2%), with ages varying from 33 to 95 years (mean of 58 years). According to risk factors for OSCC, alcohol (67.9%) and tobacco (84.5%) consumption were reported by the majority of the patients. The most common location for OSCC was the tongue (54.8%), followed by floor of the mouth (28.6%). Moreover, most patients were clinically classified as T2 (59.5%) or T3 (40.5%), and N+ (48.8%), at the time of physical examination.
Only three patients (3.6%) were not submitted to elective neck dissection, 78.6% were submitted to ipsilateral neck dissection and 17.8% were dissected bilaterally. Thirty-eight patients (45.2%) who were submitted to neck dissection were positive for lymph node metastasis (pN+), shown by histopathological analysis.
Local recurrence occurred in 25% of the patients, while regional recurrence was present in 16.7% and local and regional recurrences, simultaneously, occurred in 6% of the patients.
Most tumors, 86.9% were classified as well/moderately differentiated; and 13.1% were classified as poorly differentiated, according to the histopathological grade of tumor malignancy .
Immunohistochemical expression of moesin in oral squamous cell carcinomas
Immunohistochemical expression of moesin in the invasive front of oral squamous cell carcinomas was weak in 40 tumors, while in 44 tumors the expression was strong. A predominantly cytoplasmic moesin expression was observed in most of the tumors. The keratin pearls and some areas with more differentiated neoplastic cells showed weak/negative moesin immunoexpression (Fig. 1).
Immunohistochemical expression of podoplanin in oral squamous cell carcinomas
The expression of podoplanin in oral squamous cell carcinomas was weak in 49 tumors and strong in 35 tumors. Membranous and cytoplasmic podoplanin expression was observed in oral squamous cell carcinomas with a predominance of the membranous expression (Fig. 1).
The strong podoplanin expression was associated with post-operative radiotherapy (p = 0.004) in those patients diagnosed with squamous cell carcinomas. Podoplanin expression was not associated with the demographic and clinical features analyzed (Table 1).
Concerning microscopic features analyzed, podoplanin expression in patients with muscle infiltration was weak compared with those without infiltration (p = 0.006). Moreover, the podoplanin expression was significantly associated with lymph node metastasis (pN+). In other words, most patients with lymph node metastasis presented weak expression of podoplanin (p = 0.013), as illustrated in Table 2.
Overall analysis of podoplanin and moesin expression in oral squamous cell carcinomas was not statistically associated (p = 0.460).
Overall survival analysis
Overall survival rates varied from 0.01 to 288 months, mean of 57.2 months. Only moesin expression showed statistically significant differences (p = 0.024). The overall survival rate, in 5 years and 10 years, for patients with oral squamous cell carcinomas and strong moesin expression was reduced from 38.5%, to 23.8%, respectively. For oral squamous cell carcinomas in patients with weak moesin expression the survival rate varied from 22.7% in 5 years to 6.8% in 10 years. These differences in oral cancer patients’ survival rates for moesin expression were statistically significant (Table 3 and Fig. 2).
Based on Cox regression analysis, patients with oral squamous cell carcinomas and strong moesin expression by neoplastic epithelial cells had 1.737-fold higher chance of relative risk of death (p = 0.022), as illustrated in Table 4.
To date, the intracellular location of moesin during oral carcinogenesis has been poorly understood. Moesin translocation from plasma membrane to the cytoplasm of neoplastic cells has been demonstrated in a previous study  and it may reduce the ability to form cell-cell contacts, as well as, influence the cytoskeleton remodeling and tumor invasion process, when overexpressed in the cytoplasm . Furthermore, podoplanin linkage with the N-terminal moesin domain activates the ERM proteins, consequently inducing Rho-A phosphorylation and in the maintenance of the ERM proteins in an active form (open conformation), in the cytoplasm .
The moesin immunoprofile in the invasive front of oral squamous cell carcinomas, clinical stages II and III, was predominantly cytoplasmic and strong. Keratin pearls and some areas with more differentiated neoplastic cells showed negative moesin expression. Confirming these results, other authors described the membranous and cytoplasmic moesin expression in oral squamous cell carcinomas, [5, 9, 10]. Belbin et al. (2005) showed that membranous and cytoplasmic moesin expression increased when normal epithelium was compared with dysplastic epithelium and/or with tumor samples . The authors affirmed that moesin expression was significantly associated with head and neck squamous cell carcinomas progression. In addition, as found in the present study, the loss of moesin expression in more differentiated cells was found in keratin pearls [5, 26].
The expression of moesin was not associated with the clinical, demographic and microscopic features analyzed (p > 0.05), reinforcing previous findings [5, 7, 9, 26]. Kobayashi et al. (2004) found a significant association of moesin with the size of the tumor, but the sample analyzed varied from T1 to T4 tumors. Differently, the present study was composed of T2 and T3 tumors and no association could be found with moesin expression, as it was restricted to a limited size of tumors. According to our previous experiences with analyses of protein expression by oral neoplastic cells, the OSCCs clinically classified as T2 and T3 are better for verifying their influence on patients’ prognosis, than T1 (initial tumors) or T4 (advanced tumors).
Regarding podoplanin expression by tumor cells, as previously observed by de Vicente et al. (2015) and Tsuneki et al. (2013), the present results showed higher podoplanin expression in the earlier stages of tumors and in highly differentiated malignant cells. These studies [27,28,29] verified that podoplanin expression was inversely correlated with the degree of neoplastic epithelial cell differentiation. In agreement with the cited studies, the results found in the present study confirmed a weak/absent podoplanin expression in the majority of tumors with muscular infiltration and lymph node involvement (pN+).
Initial studies about podoplanin related strong podoplanin expression to the worst prognosis and more advanced stages of oral squamous cell carcinomas [14,15,16, 30, 31]. Instead, the present results showed the opposite side of those findings, and the authors suggest further studies should be conducted about podoplanin expression in less differentiated tumors to validate these findings.
Considering demographic and clinical features, the strong expression of podoplanin was observed mainly in those patients submitted to post-operative radiotherapy (p = 0.004) [14, 18, 19, 28, 30]; however, further studies are necessary for better evaluation of radiotherapy and podoplanin expression.
Concerning clinical stages T and N, our results failed to find an association between podoplanin expression and the clinical stages of the tumor, probably because we included only T2 and T3 tumors, while in other studies, the tumor stages varied from I to IV [14, 16, 19, 20, 30].
No statistically significant association (p = 0.460) was found between podoplanin and moesin immunoexpression by malignant cells in the invasive front of oral squamous cell carcinomas. As this was the first study about the joint expression of podoplanin and moesin in oral cancer, further investigations based on in vitro assays are necessary for better evaluation of the participation of these molecules together in the tumor invasion process.
The overall survival and the prognostic value of moesin and podoplanin expression in oral squamous cell carcinomas were analyzed in this study. Moesin expression was considered a significant prognostic factor for oral squamous cell carcinomas. The overall survival rate in 5 years was 22.7% for those patients with the strong moesin expression, while for patients with weaker moesin expression, the overall survival rate
s in 5 years was 38.5%. In ten years, overall survival rates for strong moesin expression were 6.8% and 23.8% for weak expression. Moreover, the patient with strong moesin expression presented a 1737 times higher risk of dying, compared with those with the weak expression. These results are consistent with those found by Kobayashi et al. (2004) and Schlecht et al. (2012) in oral squamous cell carcinomas and in breast cancer [6, 32].
Interestingly and corroborating the above results, a recent study conducted by Li et al. (2015) observed the knockdown of moesin in oral squamous cell carcinomas cell lines and a significantly reduction in migration and invasion . Furthermore, moesin silencing showed an increase in cell-cell adhesion. By cell spreading assay, moesin inhibition reduced filopodia formation, indicating the role of moesin in cytoskeletal modifications. This study was in agreement with the present results, which indicated that the weak expression of moesin could be related to higher survival rates in oral squamous cell carcinoma patients.
Podoplanin expression, in turn, was not considered as a significant prognostic factor for oral squamous cell carcinomas, as related by de Vicente et al. (2015) and Dos Santos Almeida et al. (2013). Although previous results considered [14,15,16, 30, 31] that strong podoplanin expression was related to poor prognosis, we could not predict the prognostic significance of podoplanin in those tumors, probably because strong podoplanin expression was related to initial tumors in earlier stages of the neoplastic cell differentiation process [27,28,29]. Therefore, considering the latest controversial studies concerning podoplanin expression, we suggest that further studies with a larger sample should be conducted to confirm the potential prognostic value of this protein in oral squamous cell carcinomas.
The weak immunohistochemical expression of moesin by neoplastic epithelial cells could be used as a favorable prognostic marker for oral squamous cell carcinomas. Additionally, the weaker expression of podoplanin was associated with lymph node involvement and muscular infiltration in oral squamous cell carcinomas, indicating that podoplanin expression occurs in more differentiated cells and at earlier stages of the tumors. Moreover, malignant cells of oral squamous cell carcinomas expressed both podoplanin and moesin, but these proteins probably act individually in tumor invasion process.
Ezrin, radixin, moesin
Oral squamous cell carcinoma
Statistical Package for the Social Sciences
Tumor size, lymph nodes and metastasis
Union for international cancer control
Deng W, Cho S, Li R. FERM domain of moesin desorbs the basic-rich cytoplasmic domain of l-selectin from the anionic membrane surface. J Mol Biol. 2013;425(18):3549–62. https://doi.org/10.1016/j.jmb.2013.06.008.
Jiang L, Phang JM, Yu J, Harrop SJ, Sokolova AV, Duff AP, et al. CLIC proteins, ezrin, radixin, moesin and the coupling of membranes to the actin cytoskeleton: a smoking gun? Biochim Biophys Acta. 2014;1838(2):643–57. https://doi.org/10.1016/j.bbamem.2013.05.025.
Li YY, Zhou CX, Gao Y. Podoplanin promotes the invasion of oral squamous cell carcinoma in coordination with MT1-MMP and rho GTPases. Am J Cancer Res. 2015;5(2):514–29.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1-2):15–33. https://doi.org/10.1007/s10555-008-9169-0.
Madan R, Brandwein-Gensler M, Schlecht NF, Elias K, Gorbovitsky E, Belbin TJ, et al. Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head Neck. 2006;28(11):1018–27. https://doi.org/10.1002/hed.20435.
Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121(8):1779–85. https://doi.org/10.1002/ijc.22923.
Schlecht NF, Brandwein-Gensler M, Smith RV, Kawachi N, Broughel D, Lin J, et al. Cytoplasmic ezrin and moesin correlate with poor survival in head and neck squamous cell carcinoma. Head Neck Pathol. 2012;6(2):232–43. https://doi.org/10.1007/s12105-011-0328-1.
Wang X, Liu M, Zhao CY. Expression of ezrin and moesin related to invasion, metastasis and prognosis of laryngeal squamous cell carcinoma. Genet Mol Res. 2014;13(3):8002–13. https://doi.org/10.4238/2014.September.29.13.
Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, et al. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res. 2004;10(2):572–80.
Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, et al. Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2005;131(1):10–8. https://doi.org/10.1001/archotol.131.1.10.
Jung WY, Kang Y, Lee H, Mok YJ, Kim HK, Kim A, et al. Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma. Histopathology. 2013;63(4):474–81. https://doi.org/10.1111/his.12202.
Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol. 1998;140(3):647–57.
Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 2005;113(6):899–910. https://doi.org/10.1002/ijc.20656.
Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107(3):563–9. https://doi.org/10.1002/cncr.22061.
Vormittag L, Thurnher D, Geleff S, Pammer J, Heiduschka G, Brunner M, et al. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy. Int J Radiat Oncol Biol Phys. 2009;73(3):913–8. https://doi.org/10.1016/j.ijrobp.2008.10.040.
Kreppel M, Scheer M, Drebber U, Ritter L, Zoller JE. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch. 2010;456(5):473–82. https://doi.org/10.1007/s00428-010-0915-7.
Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M, et al. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology. 2011;78(3):171–80. https://doi.org/10.1159/000324926.
Huber GF, Fritzsche FR, Zullig L, Storz M, Graf N, Haerle SK, et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer. 2011;129(6):1404–9. https://doi.org/10.1002/ijc.25795.
Kreppel M, Drebber U, Wedemeyer I, Eich HT, Backhaus T, Zoller JE, et al. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol. 2011;47(9):873–8. https://doi.org/10.1016/j.oraloncology.2011.06.508.
Bartuli FN, Luciani F, Caddeo F, Compagni S, Piva P, Ottria L, et al. Podoplanin in the development and progression of oral cavity cancer: a preliminary study. Oral Implantol. 2012;5(2-3):33–41.
dos Santos AA, Oliveira DT, Pereira MC, Faustino SE, Nonogaki S, Carvalho AL, et al. Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance. Anticancer Res. 2013;33(9):3969–76.
Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders’ grading in oral squamous cell carcinomas. J Oral Pathol Med. 1989;18(8):432–7.
Faustino SE, Oliveira DT, Nonogaki S, Landman G, Carvalho AL, Kowalski LP. Expression of vascular endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2008;37(4):372–8. https://doi.org/10.1016/j.ijom.2007.11.021.
Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2014;127(Pt 2):267–75. https://doi.org/10.1242/jcs.133108.
Martin-Villar E, Fernandez-Munoz B, Parsons M, Yurrita MM, Megias D, Perez-Gomez E, et al. Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell. 2010;21(24):4387–99. https://doi.org/10.1091/mbc.E10-06-0489.
Kobayashi H, Sagara J, Masumoto J, Kurita H, Kurashina K, Taniguchi S. Shifts in cellular localization of moesin in normal oral epithelium, oral epithelial dysplasia, verrucous carcinoma and oral squamous cell carcinoma. J Oral Pathol Med. 2003;32(6):344–9.
de Vicente JC, Santamarta TR, Rodrigo JP, Garcia-Pedrero JM, Allonca E, Blanco-Lorenzo V. Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival. Virchows Arch. 2015;466(5):549–58. https://doi.org/10.1007/s00428-015-1746-3.
Ohta M, Abe A, Ohno F, Hasegawa Y, Tanaka H, Maseki S, et al. Positive and negative regulation of podoplanin expression by TGF-beta and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines. Oral Oncol. 2013;49(1):20–6. https://doi.org/10.1016/j.oraloncology.2012.06.017.
Tsuneki M, Yamazaki M, Maruyama S, Cheng J, Saku T. Podoplanin-mediated cell adhesion through extracellular matrix in oral squamous cell carcinoma. Lab Invest. 2013;93(8):921–32. https://doi.org/10.1038/labinvest.2013.86.
Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 2010;177(2):1004–16. https://doi.org/10.2353/ajpath.2010.090703.
Kreppel M, Krakowezki A, Kreppel B, Drebber U, Wedemeyer I, Mauch C, et al. Podoplanin expression in cutaneous head and neck squamous cell carcinoma--prognostic value and clinicopathologic implications. J Surg Oncol. 2013;107(4):376–83. https://doi.org/10.1002/jso.23238.
Aaberg-Jessen C, Christensen K, Offenberg H, Bartels A, Dreehsen T, Hansen S, et al. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neuro-Oncol. 2009;95(1):117–28. https://doi.org/10.1007/s11060-009-9910-8.
Li YY, Zhou CX, Gao Y. Moesin regulates the motility of oral cancer cells via MT1-MMP and E-cadherin/p120-catenin adhesion complex. Oral Oncol. 2015;51(10):935–43. https://doi.org/10.1016/j.oraloncology.2015.07.003.
We would like to thank the São Paulo Research Foundation (FAPESP grant#2012/13411-6) and the National Council for Scientific and Technological Development (CNPq) for supporting the present study and the involved researchers.
This study was supported by São Paulo Research Foundation (FAPESP grant#2012/13411-6) and by the National Council for Scientific and Technological Development (CNPq). The funding body had no influence on the design of the study, the collection, analysis, and interpretation of data and the manuscript.
Availability of data and materials
The data that support the findings of this study are available in the medical records of A.C. Camargo Cancer Center, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of A.C. Camargo Cancer Center.
Ethics approval and consent to participate
This study was approved by Committee of Ethics and Research of the Bauru School of Dentistry, University of São Paulo (process #21329113.5.0000.5417), and two co-authors are physicians at A.C.Camargo Cancer Hospital, one of them is pathologist. All the surgical specimens are under responsibility and protection of the Department of Pathology of the A.C. Camargo Cancer Hospital and they can be used in research projects only after the ethics committee approval. Patients treated at A.C.Camargo must authorize the collection and storage of biological samples by signing the “Free and Informed Consent Term” and the patient’s identity is preserved throughout the process.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.